Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Esperion Therapeutics has received a consensus recommendation of "Moderate Buy" from five brokerages, with one hold rating and four buy ratings.
• The company's stock has a market capitalization of $554.46 million, with a recent price of $2.75 and a 12-month high of $3.94.
• Esperion Therapeutics reported better-than-expected quarterly earnings of ($0.02) per share, surpassing the consensus estimate by $0.15, alongside revenue of $82.39 million.

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the five research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $7.00.

Several brokerages recently issued reports on ESPR. Wall Street Zen cut Esperion Therapeutics from a "buy" rating to a "hold" rating in a research note on Monday, August 25th. HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Friday.

Esperion Therapeutics Stock Down 5.6%

NASDAQ:ESPR traded down $0.15 during midday trading on Friday, hitting $2.51. The stock had a trading volume of 7,783,821 shares, compared to its average volume of 6,327,483. Esperion Therapeutics has a one year low of $0.69 and a one year high of $3.94. The company has a market capitalization of $506.07 million, a price-to-earnings ratio of -5.12, a PEG ratio of 59.75 and a beta of 0.89. The stock has a 50-day moving average of $2.00 and a 200 day moving average of $1.43.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.15. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 35.84%.The company had revenue of $82.39 million for the quarter, compared to analysts' expectations of $62.55 million. On average, sell-side analysts anticipate that Esperion Therapeutics will post -0.29 earnings per share for the current fiscal year.

Institutional Trading of Esperion Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Meridian Wealth Management LLC bought a new stake in Esperion Therapeutics during the 1st quarter valued at $29,000. North Star Investment Management Corp. bought a new stake in Esperion Therapeutics during the 2nd quarter valued at $25,000. Sivia Capital Partners LLC bought a new stake in Esperion Therapeutics during the 2nd quarter valued at $25,000. Synergy Asset Management LLC boosted its position in Esperion Therapeutics by 3,496.3% during the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 30,138 shares in the last quarter. Finally, Rafferty Asset Management LLC bought a new stake in Esperion Therapeutics during the 4th quarter valued at $82,000. Institutional investors own 47.39% of the company's stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.